CUDEC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial

Yasuhiro Oki, Kevin R Kelly, Ian Flinn, Manish R Patel, Robert Gharavi, Anna Ma, Jefferson Parker, Amir Hafeez, David Tuck, and Anas Younes

Disclosures: YO, IF, and MP declare no disclosures to make. AY has received research support or honorarium from MSK SPORE in Lymphoma, Novel Immune Therapy of Lymphoma, Novartis, J&J, Curis, Roche, BMS, Bayer, BMS, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millenium, Genentech KK has received research funding or honorarium from Abbvie, Jannsen, Gilead, Pharmacyclics, and Amgen.

Contributions: YO, KRK, IF, MP, and AY contributed to patient recruitment and data collection. YO, KRK, IF, MP, RG, AM, JP, AH, DT and AY contributed to data analysis and interpretation. YO, KRK, IF, RG, AM, DT and AH contributed to the writing of this report. All authors have reviewed drafts of the report and approved the final version.